Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat regimen optimization with subcutaneous bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma
NL-OMON50473Phase 2Recruiting
- Sponsor
- Secura Bio
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panobinostat, bortezomib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Secura Bio. Primary endpoint: Best overall response rate up to 8 cycles. Started Feb 2017; status: recruiting.
02
Drugs
panobinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50473.